Becker's Healthcare September 27, 2024
Alexandra Murphy

AbbVie’s tavapadon has demonstrated positive results as a monotherapy for early Parkinson’s disease, according to a Sept. 26 news release from the drugmaker.

Three notes:

  1. The phase 3 Tempo-1 trial for tavapadon, a dopamine receptor partial agonist, demonstrated significant efficacy as a monotherapy in early Parkinson’s disease. Patients receiving the drug at doses of 5 milligrams and 15 milligrams showed significant reductions in the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale.
  2. In addition to the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, Pharma, Pharma / Biotech, Trends
Related Articles:
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
Pharma Pulse 10/3/24: Data Collection Complexities, 8 Things You May Not Know About Breast Cancer & more
New Techniques Make RNA Accessible to Study Variants of Uncertain Significance
Comprehensive strategies for prescription drug cost management
Gilead strikes deal to expand HIV drug access in 120 countries

Share This Article